/UTHR
United Therapeutics Corporation
UTHR • NASDAQUTHR • NASDAQ • Healthcare
$490.21-1.69%-8.44
$490.21-1.69%(-8.44)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
86Low Risk
Momentum
80Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
87.9%▼1.3pp
Revenue after COGS
Operating
46.9%▼1.0pp
After operating expenses
Net
41.9%▲0.4pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
16.2
Price vs earnings
EV/EBITDA
11.0
Enterprise value
FCF Yield
4.8%
Cash generation
Earnings Yield
6.2%
Inverse of P/E
Capital Efficiency
17
GoAI Quality ScoreStrong
ROEReturn on Equity
18.8%Strong
ROAReturn on Assets
16.9%Strong
ROICReturn on Invested Capital
15.9%Strong
Financial Health
Current RatioHealthy
6.60
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-0.86x
Debt repayment capacity (<3x)
Income QualityStrong
1.17
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B |
| Gross Profit | $2.80B | $2.57B | $2.07B | $1.79B | $1.56B |
| Gross Margin | 87.9% | 89.2% | 88.9% | 92.4% | 92.7% |
| Operating Income | $1.49B | $1.38B | $1.18B | $979.70M | $555.90M |
| Net Income | $1.33B | $1.20B | $984.80M | $727.30M | $475.80M |
| Net Margin | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% |
| EPS | $30.13 | $26.44 | $21.04 | $15.98 | $10.60 |
Average Price Target
$563.17▲ 14.9% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for United Therapeutics Corporation, the average price target is $563.17, with a high forecast of $645.00 and a low forecast of $447.00. The average price target represents a 14.9% increase from the current price of $490.21.
Highest
$645.00
Average
$563.17
Lowest
$447.00
Rating Distribution
Strong Buy
0
0%
Buy
15
50%
Hold
14
47%
Sell
1
3%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
TD Cowen● Maintain
Buy
2026-02-26Oppenheimer● Maintain
Outperform
2026-02-26Wells Fargo● Maintain
Equal Weight
2026-02-26HC Wainwright & Co.● Maintain
Buy
2026-02-26RBC Capital● Maintain
Outperform
2026-02-26UBS● Maintain
Buy
2026-01-06UBS● Maintain
Buy
2025-11-06RBC Capital● Maintain
Outperform
2025-10-30HC Wainwright & Co.● Maintain
Buy
2025-10-30Wells Fargo● Maintain
Equal Weight
2025-10-30Earnings History & Surprises
BEAT RATE
56%
Last 18 quarters
AVG SURPRISE
-0.3%
EPS vs Estimate
BEATS / MISSES
10/8
Last 18 quarters
LATEST EPS
$7.70
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+13.6%
$7.70 vs $6.78
Q4 '25
+3.9%
$7.16 vs $6.89
Q3 '25
-12.1%
$6.41 vs $7.29
Q2 '25
+5.4%
$6.63 vs $6.29
Q1 '25
-3.3%
$6.19 vs $6.40
Q4 '24
-0.6%
$6.39 vs $6.43
Q3 '24
-8.6%
$5.85 vs $6.40
Q2 '24
+9.2%
$6.17 vs $5.65
Q1 '24
+4.1%
$4.36 vs $4.19
Q4 '23
+6.7%
$5.38 vs $5.04
Q3 '23
+16.2%
$5.24 vs $4.51
Q2 '23
+7.5%
$4.86 vs $4.52
No investor questions available.
Latest News
No news available